184 related articles for article (PubMed ID: 38635728)
1. Development of a long term, ex vivo, patient-derived explant model of endometrial cancer.
van der Woude H; Phan K; Kenwright DN; Goossens L; Hally KE; Currie MJ; Kokkinos J; Sharbeen G; Phillips PA; Henry CE
PLoS One; 2024; 19(4):e0301413. PubMed ID: 38635728
[TBL] [Abstract][Full Text] [Related]
2. Endometrial ablation or resection versus levonorgestrel intra-uterine system for the treatment of women with heavy menstrual bleeding and a normal uterine cavity: a systematic review with meta-analysis.
Bergeron C; Laberge PY; Boutin A; Thériault MA; Valcourt F; Lemyre M; Maheux-Lacroix S
Hum Reprod Update; 2020 Feb; 26(2):302-311. PubMed ID: 31990359
[TBL] [Abstract][Full Text] [Related]
3. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
Zhao X; Niu J; Shi C; Liu Z
Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
[TBL] [Abstract][Full Text] [Related]
4. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
[TBL] [Abstract][Full Text] [Related]
6. Development of a patient-derived explant model for prediction of drug responses in endometrial cancer.
Collins A; Miles GJ; Powley IR; Hew R; Pringle JH; MacFarlane M; Pritchard C; Moss EL
Gynecol Oncol; 2021 Feb; 160(2):557-567. PubMed ID: 33309417
[TBL] [Abstract][Full Text] [Related]
7. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Romero SA; Young K; Hickey M; Su HI
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
[TBL] [Abstract][Full Text] [Related]
8. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Dominick S; Hickey M; Chin J; Su HI
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
[TBL] [Abstract][Full Text] [Related]
10. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.
Kim MK; Seong SJ; Kang SB; Bae DS; Kim JW; Nam JH; Lim MC; Lee TS; Kim S; Paek J
J Gynecol Oncol; 2019 Mar; 30(2):e47. PubMed ID: 30740964
[TBL] [Abstract][Full Text] [Related]
11. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby A; Hussain M; Rishworth JR; Rees MC
Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
[TBL] [Abstract][Full Text] [Related]
12. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
[TBL] [Abstract][Full Text] [Related]
13. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby AE; Cooke I; Rees M
Cochrane Database Syst Rev; 2005 Oct; (4):CD002126. PubMed ID: 16235297
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: a meta-analysis.
Fu Y; Zhuang Z
Int J Clin Exp Pathol; 2014; 7(10):6419-29. PubMed ID: 25400720
[TBL] [Abstract][Full Text] [Related]
15. Surgery versus medical therapy for heavy menstrual bleeding.
Marjoribanks J; Lethaby A; Farquhar C
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD003855. PubMed ID: 26820670
[TBL] [Abstract][Full Text] [Related]
16. Development of endometrial cancer after long-term usage of the levonorgestrel-releasing intrauterine system.
Steshenko A; Hanna L; Collins D
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33986013
[TBL] [Abstract][Full Text] [Related]
17. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review.
Buttini MJ; Jordan SJ; Webb PM
Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):316-22. PubMed ID: 19566568
[TBL] [Abstract][Full Text] [Related]
18. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
19. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
20. Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.
Kim DH; Seong SJ; Kim MK; Bae HS; Kim M; Yun BS; Jung YW; Shim JY
J Gynecol Oncol; 2017 Jan; 28(1):e1. PubMed ID: 27670255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
